Panbela Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Panbela Therapeutics.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	27.1%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Panbela Therapeutics dips 24% on pricing $6M public offering

Sep 30

Panbela Therapeutics GAAP EPS of -$1.51

Aug 15

Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth

Feb 18

Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication

Jan 06

Will Panbela Therapeutics (NASDAQ:PBLA) Spend Its Cash Wisely?

Nov 02

Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth

Jul 15

Panbela Therapeutics to join Russell Microcap Index

Jun 09

We Think Panbela Therapeutics (NASDAQ:PBLA) Can Afford To Drive Business Growth

Mar 29

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Panbela Therapeutics onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

OTCPK:PBLA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	N/A	-38	-19	-20	N/A
3/31/2024	N/A	-36	-24	-25	N/A
12/31/2023	N/A	-34	-25	-25	N/A
9/30/2023	N/A	-24	-27	-27	N/A
6/30/2023	N/A	-20	-22	-22	N/A
3/31/2023	N/A	-36	-21	-21	N/A
12/31/2022	N/A	-35	-16	-15	N/A
9/30/2022	N/A	-34	-13	-13	N/A
6/30/2022	N/A	-31	-13	-12	N/A
3/31/2022	N/A	-12	-10	-10	N/A
12/31/2021	N/A	-10	-7	-7	N/A
9/30/2021	N/A	-7	-6	-6	N/A
6/30/2021	N/A	-7	-6	-6	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-5	-4	-4	N/A
9/30/2020	N/A	-5	-4	-4	N/A
6/30/2020	N/A	-5	-3	-3	N/A
3/31/2020	N/A	-6	-3	-3	N/A
12/31/2019	N/A	-6	-3	-3	N/A
9/30/2019	N/A	-6	-2	-2	N/A
6/30/2019	N/A	-6	-2	-2	N/A
3/31/2019	N/A	-6	-3	-3	N/A
12/31/2018	N/A	-6	-2	-2	N/A
9/30/2018	N/A	-7	-3	-3	N/A
6/30/2018	N/A	-8	-3	-3	N/A
3/31/2018	N/A	-7	N/A	-3	N/A
12/31/2017	N/A	-10	N/A	-3	N/A
9/30/2017	N/A	-10	N/A	-3	N/A
6/30/2017	N/A	-10	N/A	-4	N/A
3/31/2017	N/A	-10	N/A	-3	N/A
12/31/2016	N/A	-5	N/A	-2	N/A
9/30/2016	N/A	-4	N/A	-2	N/A
6/30/2016	N/A	-3	N/A	-2	N/A
3/31/2016	N/A	-4	N/A	-4	N/A
12/31/2015	N/A	-5	N/A	-4	N/A
9/30/2015	N/A	-5	N/A	-4	N/A
6/30/2015	N/A	-6	N/A	-4	N/A
3/31/2015	N/A	-5	N/A	-4	N/A
12/31/2014	N/A	-4	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if PBLA's forecast earnings growth is above the savings rate (2.5%).

Winst versus markt: Insufficient data to determine if PBLA's earnings are forecast to grow faster than the US market

Hoge groeiwinsten: Insufficient data to determine if PBLA's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if PBLA's revenue is forecast to grow faster than the US market.

Hoge groei-inkomsten: Insufficient data to determine if PBLA's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if PBLA's Return on Equity is forecast to be high in 3 years time

Panbela Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Price target decreased to US$6.00

Price target increased to US$8.00

Forecast to breakeven in 2025

Recent updates

Nant Capital Engages in Discussions with Panbela Therapeutics

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

Panbela Therapeutics, Inc. Announces Nasdaq Files A Form 25 Notification of Removal from Listing

Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025

Panbela Announces Transfer to OTCQB Market

Panbela Therapeutics, Inc. has filed a Follow-on Equity Offering.

The Nasdaq Stock Market Notifies Panbela Therapeutics That the Nasdaq Hearings Panel Has Determined to Delist the Company’s Common Stock

The Nasdaq Stock Market Notifies Panbela Therapeutics That the Nasdaq Hearings Panel Has Determined to Delist the Company’s Common Stock

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Panbela Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(4)

Panbela Therapeutics, Inc. Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma

Panbela Therapeutics, Inc. Announces second Independent Safety Review of the ASPIRE Registration Clinical Trial

New major risk - Negative shareholders equity

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves B Cell Function in Type 1 Diabetes

New minor risk - Share price stability

Panbela Therapeutics, Inc. Announces Acceptance of Polyamine Inhibitor Car-T Combination Abstract for Online Publication

New major risk - Revenue and earnings growth

Panbela Therapeutics, Inc. Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer

Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

Panbela Therapeutics, Inc. Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.510816 million.

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Forecast to breakeven in 2025

Panbela Therapeutics Regains Compliance with Nasdaq Listing Standards

Forecast to breakeven in 2025

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.01875 million.

Panbela Therapeutics, Inc. Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

Panbela Therapeutics, Inc. Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Price target decreased to US$6.00

Panbela Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Panbela Therapeutics Receives a Notification Letter from Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Therapeutics dips 24% on pricing $6M public offering

Panbela Therapeutics Receives a Letter from The Nasdaq Stock Market LLC Regarding Minimum Stockholders' Equity Requirement

Panbela Therapeutics GAAP EPS of -$1.51

Panbela Therapeutics, Inc. Receives Approval from Australian Human Research Ethics Committee to Expand Global Clinical Trial to Australia

Panbela Therapeutics, Inc. Announces the Publication of Preclinical Data from Studies of SBP-101

Less than half of directors are independent

Panbela Therapeutics, Inc. (NasdaqCM:PBLA) completed the acquisition of Cancer Prevention Pharmaceuticals, Inc.

Panbela Therapeutics, Inc. (NasdaqCM:PBLA) completed the acquisition of Cancer Prevention Pharmaceuticals, Inc.

Panbela Therapeutics, Inc., Annual General Meeting, Jun 08, 2022

Price target increased to US$8.00

Panbela Therapeutics, Inc. (NasdaqCM:PBLA) entered into a definitive agreement to acquire Cancer Prevention Pharmaceuticals, Inc.

Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth

Panbela Presents Clinical Data on Phase 1B Clinical Trial of Sbp-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pda At 2022 Asco Gi Meeting

Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication

Panbela Therapeutics, Inc. Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines

Will Panbela Therapeutics (NASDAQ:PBLA) Spend Its Cash Wisely?

Director Jennifer Simpson has joined 3rd company board

Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth

Panbela Therapeutics to join Russell Microcap Index

Panbela Therapeutics, Inc. Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2021 ASCO Annual Meeting

Forecast to breakeven in 2025

We Think Panbela Therapeutics (NASDAQ:PBLA) Can Afford To Drive Business Growth

Panbela Therapeutics Inc. Provides Update on Current Clinical Trial: Decision to Hold Administration of SBP-101

New 90-day high: US$4.93

Panbela Therapeutics, Inc. Completes Enrollment in Its Phase 1B Trial Investigating SBP-101 Combination Therapy for First Line Metastatic Pancreatic Cancer

New 90-day high: US$4.37

Independent Director recently bought US$63k worth of stock

Sun BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $10.5 million.

Sun Biopharma, Inc. Announces Appointment of Jennifer K. Simpson, Ph.D., as Chief Executive Officer

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven